Advertisement
AMLX vs LRMR
Which Stock Would AI Choose? Amylyx Pharmaceuticals (AMLX) vs. Larimar Therapeutics (LRMR) Stock Comparison
Key Takeaways
- Amylyx Pharmaceuticals enters this comparison with a de-risked late-stage asset after positive Phase 3 data, while Larimar Therapeutics remains earlier in its regulatory journey.
- Both companies are pre-revenue biotechnology firms, but AMLX holds a substantially larger cash balance (roughly $768 million) than LRMR (about $156 million).
- Relative performance diverges sharply: AMLX has posted strong year-to-date gains, while LRMR has pulled back in recent weeks despite a favorable analyst consensus.
- Tickeron AI Verdict: Based on observable trend consistency, catalyst strength, and capital positioning, the AI would currently favor AMLX over LRMR.
- Explore more on these names through AMLX Major News and AMLX Today's Price Move, as well as LRMR Major News and LRMR Today's Price Move.
- To see how automated systems are positioning across the market, explore Trending AI Robots.
Introduction
This stock comparison examines two clinical-stage biotechnology companies with distinct profiles: Amylyx Pharmaceuticals and Larimar Therapeutics. Both trade on the Nasdaq and both are developing therapies for serious, underserved medical conditions, yet they sit at different stages of the development lifecycle and carry different risk-and-reward characteristics. Investors and traders evaluating relative performance, market positioning, and near-term catalysts may find this comparison useful for understanding how momentum, cash resources, and regulatory progress shape sentiment. While neither company currently generates product revenue, their recent trajectories highlight how a single clinical outcome or financing event can dramatically reshape a stock's outlook.
AMLX Overview and Recent Performance
AMLX, Amylyx Pharmaceuticals, is a biopharmaceutical company focused on endocrine and neurodegenerative conditions. Its lead program, avexitide, is a GLP-1 receptor antagonist being developed for post-bariatric hypoglycemia (PBH), a condition of recurrent low blood sugar that can follow weight-loss surgery. Recent market activity has centered on positive topline results from the Phase 3 LUCIDITY trial, which showed a 55% reduction in severe hypoglycemic events versus placebo and met all secondary endpoints. The company followed the readout with an oversubscribed equity offering that raised roughly $545 million in net proceeds, lifting its cash position to about $768 million. Amylyx has signaled that a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) remains on track for the end of 2026, positioning avexitide as a potential first approved therapy for PBH. This catalyst pipeline has supported a meaningful re-rating in the shares in recent weeks.
LRMR Overview and Recent Performance
LRMR, Larimar Therapeutics, is a clinical-stage biotechnology company developing treatments for rare diseases using a cell-penetrating peptide platform. Its lead candidate, nomlabofusp (also known as CTI-1601), targets Friedreich's ataxia, a rare, progressive, and ultimately fatal neurodegenerative disorder. In recent months, Larimar has advanced its regulatory pathway, submitting the first module of a rolling Biologics License Application (BLA) and reporting positive open-label data showing sustained increases in frataxin protein levels. The company has also strengthened its executive team with a new president and chief operating officer. Despite a broadly positive analyst consensus and notable price-target upside, the stock has pulled back over the trailing several weeks, with its 52-week range reflecting considerable volatility. Larimar's cash balance of roughly $156 million is projected to fund operations into the third quarter of 2027.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading systems drawn from hundreds of AI Trading Bots that collectively monitor and trade thousands of different tickers. Rather than displaying every available bot, this section highlights the ones best suited to prevailing market conditions, making it easier for traders to identify systems with relevant momentum. The bots featured there span a wide range of trading styles, strategies, timeframes, performance statistics, and ticker coverage, so no two are alike. Because market regimes shift, the curated list is updated to reflect which approaches are currently most aligned with the environment. For traders seeking a data-driven way to track names like AMLX and LRMR, reviewing the Trending AI Robots section can offer a useful starting point for further research.
Head-to-Head Comparison
The two companies differ most clearly in development stage and financial scale. Amylyx has completed a pivotal Phase 3 trial with positive results and is preparing for a near-term NDA filing, whereas Larimar is earlier in the process, advancing a rolling BLA built partly on a surrogate biomarker endpoint. On growth drivers, Amylyx's near-term story is tied to a potential 2027 launch in PBH, a condition with no currently approved therapy, while Larimar's outlook hinges on the regulatory acceptance and eventual commercialization of nomlabofusp in Friedreich's ataxia. Risk factors also differ: Amylyx faces launch-execution and market-access questions, including pricing and payer coverage, while Larimar carries more binary regulatory and manufacturing risk, along with a smaller cash runway. Sector exposure is similar, as both are pre-commercial biotechnology names sensitive to clinical, regulatory, and financing headlines. Market sentiment currently reflects Amylyx's de-risked catalyst, whereas Larimar's favorable analyst ratings have not fully translated into recent price momentum.
Tickeron AI Verdict
Based on observable factors such as trend consistency, the strength and recency of positive catalysts, cash positioning, and the proximity of a defined regulatory milestone, Tickeron's AI would likely favor AMLX over LRMR in the current environment. Amylyx combines a completed positive Phase 3 readout, a substantially larger capital base, and a near-term NDA submission, which together provide a comparatively more stable and actionable setup. Larimar offers meaningful long-term upside and a strong analyst consensus, but its earlier-stage regulatory path and recent relative weakness introduce greater uncertainty. This assessment reflects a probabilistic evaluation of relative positioning rather than a definitive prediction of future performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMLX is a StrongBuy and LRMR is a Hold.
Aroon Indicator for AMLX shows an upward move is likely
AMLX's Aroon Indicator triggered a bullish signal on November 10, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 218 similar instances where the Aroon Indicator showed a similar pattern. In 189 of the 218 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AMLX's RSI Indicator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on AMLX as a result. In 65 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for AMLX just turned positive on October 20, 2026. Looking at past instances where AMLX's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.
AMLX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMLX advanced for three days, in 233 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
AMLX broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. AMLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.481) is normal, around the industry mean (6.379). P/E Ratio (-20.922) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.627) is also within normal values, averaging (183.387).
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
LRMR's RSI Indicator climbs out of oversold territory
The RSI Indicator for LRMR moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 30 of the 34 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on LRMR as a result. In 76 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for LRMR just turned positive on October 21, 2026. Looking at past instances where LRMR's MACD turned positive, the stock continued to rise in 45 of 51 cases over the following month. The odds of a continued upward trend are 88%.
Following a +12.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where LRMR advanced for three days, in 214 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
LRMR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 56 cases where LRMR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LRMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for LRMR entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.949) is normal, around the industry mean (3.498). P/E Ratio (-1.189) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. LRMR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LRMR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
LRMR | ||
|---|---|---|
OUTLOOK RATING 1..100 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 58 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 78 | |
P/E GROWTH RATING 1..100 | 13 | |
SEASONALITY SCORE 1..100 | 38 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| AMLX | LRMR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 87% | 2 days ago 88% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 81% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 88% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 81% |
| Advances ODDS (%) | 2 days ago 80% | 2 days ago 84% |
| Declines ODDS (%) | 17 days ago 81% | 10 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 75% | 2 days ago 71% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMLX’s FA Score shows that 0 FA rating(s) are green while LRMR’s FA Score has 1 green FA rating(s).
- AMLX’s FA Score: 0 green, 5 red.
- LRMR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMLX’s TA Score shows that 6 TA indicator(s) are bullish while LRMR’s TA Score has 5 bullish TA indicator(s).
- AMLX’s TA Score: 6 bullish, 3 bearish.
- LRMR’s TA Score: 5 bullish, 3 bearish.
Price Growth
AMLX (@Pharmaceuticals: Generic) experienced а +5.86% price change this week, while LRMR (@Biotechnology) price change was +5.91% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
AMLX is expected to report earnings on Mar 09, 2027.
LRMR is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.20% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
LRMR and
Correlation & Price change
A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with AMLX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then AMLX could also see price increases.
| Ticker / NAME | Correlation To LRMR | 1D Price Change % | ||
|---|---|---|---|---|
| LRMR | 100% | +6.32% | ||
| AMLX - LRMR | 45% Loosely correlated | +2.32% | ||
| CLDX - LRMR | 44% Loosely correlated | -1.89% | ||
| VIR - LRMR | 44% Loosely correlated | -3.63% | ||
| MLTX - LRMR | 42% Loosely correlated | -0.48% | ||
| SLDB - LRMR | 41% Loosely correlated | +2.14% | ||
More | ||||